Genmab

Beleggen in aandelen beurzen Frankfurt DAX, Londen FTSE 100, Parijs CAC40, etc.
Plaats reactie
Gebruikersavatar
Jojo
Premiummember
Premiummember
Berichten: 496
Lid geworden op: 19 Dec 2013 15:26
waarderingen: 151
Contact:

Re: Genmab

Berichtdoor Jojo » 05 Jan 2018 13:52

Gilead Ageas Genmab ASMI Sphere3D GSK CFEB LBrands Melexis Umicore Euronav Nordex Solvay Grandvision Biocartis AXA Befimmo AHDelh ABInbev TCON ACIU BMW RioTinto


Gebruikersavatar
Jojo
Premiummember
Premiummember
Berichten: 496
Lid geworden op: 19 Dec 2013 15:26
waarderingen: 151
Contact:

Re: Genmab

Berichtdoor Jojo » 26 Jan 2018 08:44

Genmab GEN.CO : UBS starts with buy, DKR 1400 target price
Gilead Ageas Genmab ASMI Sphere3D GSK CFEB LBrands Melexis Umicore Euronav Nordex Solvay Grandvision Biocartis AXA Befimmo AHDelh ABInbev TCON ACIU BMW RioTinto

brando
Forum newbie
Forum newbie
Berichten: 12
Lid geworden op: 03 Apr 2014 10:19
waarderingen: 3
Contact:

Re: Genmab

Berichtdoor brando » 21 Feb 2018 18:19

Jojo liked last!
in port: Suez @ 11.91, Argenx @ 65.82, kiadis @ 13.42, genmab @ 1151 dkk, Thrombogenics @ 22 :-(

tomulnrs
Forum verkenner
Forum verkenner
Berichten: 92
Lid geworden op: 25 Jan 2018 16:12
waarderingen: 35
Contact:

Re: Genmab

Berichtdoor tomulnrs » 22 Feb 2018 09:52

Heel erg puike Resultaten.
Nog beter als de expectations.
Na enkele heel slechte maanden schiet het aandeel eindelijk nog eens 18% omhoog. Hopelijk blijft het nu in een opwaartse trend.
Jojo liked last!
Port:
NL: Pharming, Ahold, Kiadis, BAM, PostNL, AMG
BE: Galapagos, Mithra, Melexis, ArgenX, ABI, Vastned, KBCA
EU: Genmab, Vodafone, X-Fab
US: Keryx, Synergy, Ballard, Disney, Mastercard

Gebruikersavatar
Jojo
Premiummember
Premiummember
Berichten: 496
Lid geworden op: 19 Dec 2013 15:26
waarderingen: 151
Contact:

Re: Genmab

Berichtdoor Jojo » 22 Feb 2018 18:05

Hopelijk terug op weg naar de 1400 Dkk
Gilead Ageas Genmab ASMI Sphere3D GSK CFEB LBrands Melexis Umicore Euronav Nordex Solvay Grandvision Biocartis AXA Befimmo AHDelh ABInbev TCON ACIU BMW RioTinto

brando
Forum newbie
Forum newbie
Berichten: 12
Lid geworden op: 03 Apr 2014 10:19
waarderingen: 3
Contact:

Re: Genmab

Berichtdoor brando » 26 Feb 2018 09:50

komt goed no worries en sneller dan je denkt.
in port: Suez @ 11.91, Argenx @ 65.82, kiadis @ 13.42, genmab @ 1151 dkk, Thrombogenics @ 22 :-(

tomulnrs
Forum verkenner
Forum verkenner
Berichten: 92
Lid geworden op: 25 Jan 2018 16:12
waarderingen: 35
Contact:

Re: Genmab

Berichtdoor tomulnrs » 26 Feb 2018 10:15

brando schreef:komt goed no worries en sneller dan je denkt.


Zeker wel.
Samen met Galapagos verwacht ik op korte termijn zeker wel wat goed nieuws, en dit waarbij het risico heel laag is, in tegenstelling tot de normale (kleine) biotech-bedrijven die het vaak van 1 product moeten hebben.
Port:
NL: Pharming, Ahold, Kiadis, BAM, PostNL, AMG
BE: Galapagos, Mithra, Melexis, ArgenX, ABI, Vastned, KBCA
EU: Genmab, Vodafone, X-Fab
US: Keryx, Synergy, Ballard, Disney, Mastercard

tomulnrs
Forum verkenner
Forum verkenner
Berichten: 92
Lid geworden op: 25 Jan 2018 16:12
waarderingen: 35
Contact:

Re: Genmab

Berichtdoor tomulnrs » 18 Apr 2018 00:58

Opnieuw een mooie dag voor Genmab-beleggers :)
Port:
NL: Pharming, Ahold, Kiadis, BAM, PostNL, AMG
BE: Galapagos, Mithra, Melexis, ArgenX, ABI, Vastned, KBCA
EU: Genmab, Vodafone, X-Fab
US: Keryx, Synergy, Ballard, Disney, Mastercard

tomulnrs
Forum verkenner
Forum verkenner
Berichten: 92
Lid geworden op: 25 Jan 2018 16:12
waarderingen: 35
Contact:

Re: Genmab

Berichtdoor tomulnrs » 28 Mei 2018 09:32

Genmab Announces that Janssen Will Stop Studies of Daratumumab in Combination with Anti-PD-(L)1

Copenhagen, Denmark; May 26, 2018 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that following a planned review, the DMC has recommended that the Phase Ib/II study (CALLISTO/LUC2001) of daratumumab in combination with atezolizumab versus atezolizumab monotherapy in patients with previously treated advanced or metastatic non-small cell lung cancer should be terminated. In addition the phase I MMY2036 study of daratumumab plus JNJ-63723283, an anti PD-1 antibody in patients with multiple myeloma will be discontinued.

The DMC determined that there was no observed benefit within the combination treatment arm, daratumumab plus atezolizumab, over atezolizumab monotherapy, and recommended termination of the study. In addition to the lack of benefit, the DMC noted a numerical increase in mortality-related events in the combination arm.

Based on these findings, Janssen has made the decision also to discontinue the MMY2036 study, which was evaluating a combination of daratumumab and anti-PD-1 (JNJ-63723283) in patients with Multiple Myeloma. Janssen has informed Health Authorities about these events and has contacted its partner companies conducting daratumumab and anti-PD-(L)1 combination studies to discuss ceasing enrollment and dosing of the combination while the data is being further investigated.

In August 2012, Genmab granted Janssen an exclusive worldwide license to develop, manufacture and commercialize daratumumab.

“While we are disappointed that the studies will be discontinued, Genmab fully supports Janssen’s decision as patient safety is paramount in drug development. We look forward to gaining a better understanding of the data upon further analysis. We are pleased that the development program for daratumumab remains expansive and continues to benefit patients with Multiple Myeloma” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.
Port:
NL: Pharming, Ahold, Kiadis, BAM, PostNL, AMG
BE: Galapagos, Mithra, Melexis, ArgenX, ABI, Vastned, KBCA
EU: Genmab, Vodafone, X-Fab
US: Keryx, Synergy, Ballard, Disney, Mastercard

tomulnrs
Forum verkenner
Forum verkenner
Berichten: 92
Lid geworden op: 25 Jan 2018 16:12
waarderingen: 35
Contact:

Re: Genmab

Berichtdoor tomulnrs » 28 Mei 2018 09:34

Slecht nieuws natuurlijk.
Studie stopzetten is nachtmerrie voor elke biotech.
Maar beursreactie is er zwaar over.
Compleet geshort.
Ik koop bij.
Genmab‘s pipeline zit nog boordevol...
Port:
NL: Pharming, Ahold, Kiadis, BAM, PostNL, AMG
BE: Galapagos, Mithra, Melexis, ArgenX, ABI, Vastned, KBCA
EU: Genmab, Vodafone, X-Fab
US: Keryx, Synergy, Ballard, Disney, Mastercard